|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis显示文摘Obeticholic acid(OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be effective against liver fibrosis, possibly due to the lower dosage to reduce the incidence of the side-effect of pruritus. Here we propose a combinatory therapeutic strategy of OCA and apoptosis inhibitor for combating against liver fibrosis. CCl4-injured mice, D-galactosamine/LPS(GalN/LPS)-treated mice and cycloheximide/TNFα(CHX/TNFα)-treated HepG2 cells were employed to assess the effects of OCA, or together with IDN-6556, an apoptosis inhibitor. OCA treatment significantly inhibited hepatic stellate cell(HSC)activation/proliferation and prevented fibrosis. Elevated bile acid(BA) levels and hepatocyte apoptosis triggered the activation and proliferation of HSCs. OCA treatment reduced BA levels but could not inhibit hepatocellular apoptosis. An enhanced anti-fibrotic effect was observed when OCA was co-administrated with IDN-6556. Our study demonstrated that OCA inhibits HSCs activation/proliferation partially by regulating BA homeostasis and thereby inhibiting activation of HSCs. The findings in this study suggest that combined use of apoptosis inhibitor and OCA at lower dosage represents a novel therapeutic strategy for liver fibrosis. | Jiyu Zhou Ningning Huang Yitong Guo Shuang Cui Chaoliang Ge Qingxian He Xiaojie Pan Guangji Wang Hong Wang Haiping Hao | 2019 | Acta Pharmaceutica Sinica B2019，9，3： | 13 |
| 2 | Engineering optimization approach of nonaqueous electrolyte for sodium ion battery with long cycle life and safety显示文摘Electrolyte design strategies are closely related to the capacities, cycle life and safety of sodium–ion batteries. In this study, we aimed to optimize electrolyte with the focus on engineering aspects. The basic physicochemical properties including ionic conductivity, viscosity,wettability and thermochemical stability of the electrolytes using Na PF6 as the solute and the mixed solvent with different components of EMC,DMC or DEC in PC or EC were systematically measured. Ah pouch cell with NaNi_(1/3)Fe_(1/3)Mn_(1/3)O_(2)/hard carbon electrodes was used to evaluate the performance of the prepared electrolytes. By using the Inductive Coupled Plasma Emission Spectrometer(ICP), X-ray photoelectron spectroscopy(XPS), Thermogravimetric-differential scanning calorimetry(TG-DSC) and Accelerating Rate Calorimeter(ARC), we show that an optimized electrolyte can effectively promote the formation of a protective interfacial layer on two electrodes, which not only retards parasitic reactions between the electrodes and electrolyte but also suppresses dissolution of metal ions from the cathode. With an optimized electrolyte, a NaNi_(1/3)Fe_(1/3)Mn_(1/3)O_(2)/hard carbon cell can attain 56.16% capacity retention under the low temperature of -40℃, and can be able to retain 80%capacity retention after more than 2500 cycles while presenting excellent thermal safety. | Haiying Che Xinrong Yang Yan Yu Chaoliang Pan Hong Wang Yonghong Deng Linsen Li Zi-Feng Ma | 2021 | Green Energy & Environment2021，6，2： | 4 |
| 3 | Phase singularities and spectral changes of spectrally partially coherent higher order Bessel-Gauss pulsed beams显示文摘 | Ding Chaoliang Pan Liuzhan Lti Baida | 2009 | J Opt Soc Am A2009，26，12： | 1 |
| 4 | METTL9 mediated N1-histidine methylation of zinc transporters is required for tumor growth显示文摘Dear Editor,Histidine methylation has been known for many years(Searle and Westall,1951),but only a few proteins carrying such modifications have been studied(Webb et al.,2010;Al-Hadid et al.,2014;Kwiatkowski et al.,2018;Guo et al.,2019;Wilkinson et al.,2019;Kwiatkowski and Drozak,2020). | Mengyue Lv Dan Cao Liwen Zhang Chi Hu Shukai Li Panrui Zhang Lianbang Zhu Xiao Yi Chaoliang Li Alin Yang Zhentao Yang Yi Zhu Kaiguang Zhang Wen Pan | 2021 | Protein & Cell2021，12，12： | 0 |
| 5 | Tumorigenicity risk of iPSCs in vivo:nip it in the bud显示文摘In 2006,Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4,Sox2,Klf44,and c-Myc.Since then,the future clinical application of somatic cell reprogramming technology has become an attractive research topic in the field of regenerative medicine.Of note,considerable interest has been placed in circumventing ethical issues linked to embryonic stem cell research.However,tumorigenicity,immunogenicity,and heterogeneity may hamper attempts to deploy this technology therapeutically.This review highlights the progress aimed at reducing induced pluripotent stem cells tumorigenicity risk and howto assess the safety of induced pluripotent stem cells cell therapy products. | Chaoliang Zhong Miao Liu Xinghua Pan Haiying Zhu | 2022 | Precision Clinical Medicine2022，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员